香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Science and Education Industry Group Limited 中國科教產業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1756） 截 至2025年2月28日止六個月之中期業績公告 董事會欣然公佈本集團截至2025年2月28日止六個月之未經審計綜合中期業績， 連 同2024年同期之比較數字。 摘 要 | | 於2025年 | 於2024年 | | | | | --- | --- | --- | --- | --- | --- | | | 2月28日 | 2月29日 | 變 動 | | 百分比變動 | | 學校數目 | 3 | 3 | | – | – | | 就讀學生人數 | 56,056 | 54,077 | 1,979 | | 3.7% | | | 截 至 | 截 至 | | | | | | 2025年 | 2024年 | | | | | | 2月 ...

目 錄 2 公司資料 3 董事簡介 6 主席報告書 13 管理層之討論及分析 18 董事會報告書 29 企業管治報告書 38 財務報表 38 綜合損益表 40 綜合全面收益表 41 綜合財務狀況表 43 綜合權益變動表 45 綜合現金流量表 47 財務報表附註 120 獨立核數師報告 125 主要物業表 127 已公佈五年財務摘要 公司資料 董事 執行董事 羅旭瑞（主席兼行政總裁） 羅俊圖（副主席兼董事總經理） 羅寶文（副主席） 黃寶文（首席營運官） 梁蘇寶（首席財務官） 吳季楷 獨立非執行董事 龐述英，OBE，JP 簡麗娟 李家暉，MH 石禮謙，GBS，JP 審計委員會 李家暉，MH（主席） 龐述英，OBE，JP 簡麗娟 石禮謙，GBS，JP 薪酬委員會 簡麗娟（主席） 羅旭瑞 龐述英，OBE，JP 李家暉，MH 提名委員會 羅旭瑞（主席） 龐述英，OBE，JP 簡麗娟 李家暉，MH 石禮謙，GBS，JP 秘書 林秀芬 核數師 安永會計師事務所 執業會計師 註冊公眾利益實體核數師 主要往來銀行 澳新銀行集團有限公司 交通銀行（香港）有限公司 東亞銀行有限公司 中國工商銀行（亞洲）有限公司 開曼群島股份登記處 ...

Financial Performance - For the year ended December 31, 2024, the Group recorded an annual revenue of RMB 7,949,439,000, representing a decrease of 24.2% compared to the previous year[14]. - The Group achieved a net profit of RMB 111,245,000 for the full year of 2024, an increase of 60.2% compared to the previous year[17]. - Profit attributable to owners of the Company increased to RMB 50,621,000, representing an increase of 115.6% compared to the previous year[17]. - The gross profit for the year was RMB 860,097,000, reflecting a decrease of 17.1% year-on-year, with a gross profit margin improvement to 10.8% from 9.9%[181]. - Other income, including bank interest and government grants, totaled RMB 284,624,000, an increase of 32.7% year-over-year[187]. - Selling and distribution costs decreased by 42.1% to RMB 80,873,000, attributed to lower business volume and changes in warranty expense accounting[193]. - General and administrative expenses were RMB 429,816,000, down 13.7% from the previous year, reflecting ongoing cost control measures[198]. - Research and development expenses amounted to RMB 282,187,000, a modest decrease of 7.9% year-over-year, aligned with the Group's business level[199]. - Finance costs for the year were RMB 115,997,000, slightly down 3.7% due to reduced bank borrowing costs[200]. - The Group reported a net loss from associates of RMB 63,140,000, primarily due to losses from Wuling New Energy and FL Seating, despite some profitable results from other associates[191]. Revenue Breakdown - The total revenue of the vehicles' power supply systems division for the year ended December 31, 2024, was RMB 1,737,084,000, representing a decrease of 30% compared to the previous year[73]. - The total revenue of the automotive components and other industrial services division for the year ended December 31, 2024, was RMB 5,460,853,000, representing a decrease of approximately 10.9% compared to the previous year[105]. - The commercial vehicles assembly division recorded a revenue of RMB 718,758,000 in 2024, representing a decrease of 60.9% compared to the previous year[42]. - Wuling New Energy achieved total revenue of RMB 1,016,937,000 for the year, representing an increase of approximately 29.5% compared to the previous year[157]. - The Group's revenue from the new energy vehicle business reached RMB 1,020 million, a 29.5% year-on-year growth, despite ongoing operational losses[48]. Market and Business Strategy - The decrease in revenue was primarily due to reduced business volume in the vehicles' power supply systems division and the commercial vehicles assembly segment[14]. - The Group focused on maintaining relationships with key customers while expanding its customer base in external markets[21]. - The Group is actively seeking new cooperation opportunities to address challenges posed by intensified market competition[21]. - The Group aims to establish a stable foundation for emerging business areas to mitigate cyclical downturns in the market[14]. - The Group's repositioning strategy on refitted vehicles since the second half of 2023 impacted the commercial vehicles assembly segment[14]. - The Group intends to develop high value-added segments in the refitted vehicles business, focusing on customized markets such as cold chain and medical services[62]. - The Group will continue to deepen the management of loss-making enterprises, implementing targeted measures to address their shortcomings[65]. - The Group aims to enhance product quality and expand both domestic and international markets under the guidance of the "LINXYS Project"[68]. Product Development and Innovation - The automotive components division achieved a revenue of approximately RMB 729 million in 2024, more than doubling compared to the previous year[24]. - The production and sales of new-energy rear axles exceeded 1.5 million units cumulatively since product launch[24]. - The company successfully developed a new generation of new energy electric rear axles and three-in-one motor electric control systems, which are now applied in projects for major manufacturers[24]. - The M20B high thermal efficiency engine was successfully launched in 2023 and has become a mainstream product for the division, contributing positively to business performance[90]. - The successful completion of the new generation of H-series ultra-high-efficiency engines and other multi-fuel engines has enhanced the company's competitive edge in the industry[88]. - The division has laid out a comprehensive plan for power integration products covering HEV, PHEV, REEV, and BEV technical routes, aimed at meeting the needs of automobile manufacturers[91]. - The company is committed to implementing cost control measures to alleviate losses in a tough operating environment[76]. Customer and Sales Performance - The company secured supply orders from new customers, effectively offsetting negative impacts from declining demand from existing major customers[32]. - Sales volume of refrigerated trucks reached 769 units in 2024, marking a 6% year-on-year increase and a cumulative market share of approximately 11%[40]. - The fire truck business secured sales orders totaling approximately RMB 150 million, including around 97 units of various fire vehicles, capitalizing on state support for emergency projects[40]. - The off-road vehicle business achieved annual sales of 3,097 units in 2024, actively expanding into overseas markets[40]. - The new energy vehicle business saw total sales of 14,166 units, reflecting a 41.3% year-on-year increase, with domestic sales reaching 12,060 units, a 16% increase[46]. - Wuling New Energy launched several new products, including the long-range version of the Golden Small Truck, contributing to a 57.8% year-on-year increase in exports to Japan and Korea, totaling 803 units[46]. Operational Efficiency and Cost Control - The Group aims to enhance operational efficiency through a differentiated performance appraisal and remuneration allocation system, encouraging business units to challenge high goals[53]. - The Group is focused on increasing revenue and reducing expenditures, implementing the "Four Increases, One Stabilisation and Four Enhancements" strategy to improve asset efficiency[57]. - The Group will strengthen internal management and budgetary control to achieve operational targets while promoting the "Three Reductions" initiative to minimize capital occupation and operating costs[64]. - Despite the decline in business volume, the division managed to maintain profitability with an operating profit of RMB 75,919,000 for the year[132]. Challenges and Market Conditions - The decline in refitted vehicle sales was primarily due to the Group's repositioning strategy and weak market demand resulting from an unfavorable economic environment[135]. - The Group completed the restructuring of its new energy vehicle business in late 2022, transferring assembly operations to Wuling New Energy, which has affected the business volume of refitted vehicles[133]. - The Group's overseas production plants in Indonesia experienced lower business volume due to delays in customer orders, but there is optimism for future growth in the Indonesian automobile industry[123]. - The Indian production plant maintained profitability in 2024, targeting the automotive component business of a renowned PRC car manufacturer[124].

2024 ANNUAL REPORT 年報 YUANDA CHINA HOLDINGS LIMITED 遠大中國控股有限公司 (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） Stock Code 股票代碼：2789 科技引領市場 服務創造價值 Technology Leads Markets, Services Create Value Annual Report 2024 年 報 YUANDA CHINA HOLDINGS LIMITED 遠大中國控股有限公司 Contents 目錄 | Corporate Information | | | --- | --- | | 集團資料 | 2 | | Financial Highlights | 5 | | 財務摘要 | | | Corporate Culture & Mission | 6 | | 企業文化及使命 | | | Chairman's Statement 主席報告 | 7 | | Management Discussion and Analys ...

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 4,446,120, an increase of 9.1% from RMB 4,076,680 in 2023[9] - Gross profit for 2024 was RMB 1,329,473, with a gross margin of 29.9%, down from 31.6% in 2023[9] - Net profit for 2024 was RMB 598,332, representing a decrease of 12.6% compared to RMB 684,948 in 2023, resulting in a net profit margin of 13.5%[9] - EBITDA for the year was RMB 1.11 billion, indicating steady growth and maintaining industry-leading operational efficiency[20] - The company’s hospital business revenue was RMB 4.32 billion, up 11.1% from the previous year, with outpatient service revenue increasing by 20.8%[21] - The company completed 96,993 surgeries during the year, a 15.8% increase compared to the previous year, with surgical revenue rising by 21.2%[22] - The company continues to expand its oncology-related business, with revenue increasing from RMB 1.78 billion to RMB 1.96 billion, a growth of 10.4%[23] - The group achieved a record revenue of RMB 4.45 billion for the fiscal year ending December 31, 2024, representing a 9.1% increase year-over-year[20] - The company's gross profit increased by 3.4% from RMB 1,286.3 million to RMB 1,329.5 million, with a gross margin of 29.9% for the year ending December 31, 2024[63] - The company’s total liabilities decreased by 5.0% to RMB 4.25 billion, reflecting effective cost management strategies[20] Assets and Liabilities - The total current assets as of December 31, 2024, were RMB 1,825,749, a decrease from RMB 1,975,590 in 2023[9] - The total non-current assets increased to RMB 9,103,506 in 2024 from RMB 8,758,973 in 2023[9] - Total assets increased by 1.8% from RMB 10,734.6 million as of December 31, 2023, to RMB 10,929.3 million as of December 31, 2024[81] - Trade receivables decreased by 4.7% from RMB 864.0 million as of December 31, 2023, to RMB 823.0 million as of December 31, 2024[83] - Trade payables decreased by 20.1% from RMB 687.1 million as of December 31, 2023, to RMB 549.0 million as of December 31, 2024[85] - Other payables decreased by 18.7% from RMB 723.0 million as of December 31, 2023, to RMB 587.5 million as of December 31, 2024[85] Operational Efficiency and Growth - The company operates 16 hospitals focused on oncology across 13 cities in 8 provinces in China, aiming to address the significant demand for cancer treatment in non-first-tier cities[11] - The company emphasizes a standardized management model to support both organic growth and acquisitions, enhancing operational efficiency[12] - The number of patient visits reached approximately 4.5 million, a year-over-year increase of 23.8%[20] - The group has a total of 7,607 medical professionals as of December 31, 2024, an increase of 124 from the previous year, including 1,236 senior title professionals[31] - The group has established a multidisciplinary collaboration for complex cases, enhancing the quality of medical services and patient care[35] Patient Care and Satisfaction - Patient satisfaction improved to 97.03%, an increase of 0.91 percentage points from the previous year[19] - The group achieved a patient satisfaction rate of 97.03% in 2024, an increase of 0.91 percentage points from 2023, with a goal of reaching 100% satisfaction[38] - The group’s internet hospital registered nearly 230,000 consultations during the reporting period, enhancing patient access to healthcare services[37] Technology and Innovation - The company is actively embracing AI technology in various medical applications to enhance operational efficiency and patient experience[19] - AI technology has improved the detection rate of small lung nodules by 10%-15% compared to traditional methods, and reduced chest CT report generation time by 50%-70%[39] - The company is actively embracing new technologies, including AI imaging recognition, to enhance diagnostic efficiency and patient experience[58] Strategic Initiatives - The company is actively pursuing a merger and acquisition strategy to capitalize on industry consolidation opportunities[15] - The company is focused on expanding its market presence and improving service capabilities in response to the government's health service capacity enhancement initiatives for 2024[52] - The company is exploring strategic acquisitions to enhance its service offerings and market presence[200] Employee and Governance - The group has 8,169 full-time employees as of December 31, 2024, a decrease from 8,238 employees as of December 31, 2023[101] - The total employee compensation, including directors' remuneration, amounted to RMB 1,456.1 million for the year ending December 31, 2024, compared to RMB 1,335.9 million for the year ending December 31, 2023[164] - The company has established a comprehensive labor protection and compensation system to safeguard employee rights and enhance core competitiveness through a dual-channel promotion mechanism[49] Market Outlook - The private oncology medical service market in China is projected to grow at a compound annual growth rate (CAGR) of 19.8%, reaching RMB 1,092 million by 2026[56] - The overall oncology medical service market in China is expected to reach RMB 7,687 million by 2026, with a CAGR of 11.6% from 2022 to 2026[56] - Future outlook suggests a 70% target for revenue growth in the next fiscal year[200] Regulatory and Compliance - The group faces significant risks including unpredictable regulatory reforms in China's healthcare sector, which could adversely affect operations and future development[133] - The management highlighted a commitment to maintaining a 100% compliance rate with regulatory standards[200] - The group has implemented internal policies and processes for environmental protection and has complied with all relevant environmental laws and regulations during the reporting period[136] Community Engagement - The group is actively involved in community service and medical charity activities, enhancing its brand influence and social impact[45]

ANNUAL REPORT 2024 年度報告 雲 (Incorporated in the Cayman Islands with Limited Liability) 股份代號 Stock Code : 00484 （於開曼群島註冊成立的有限公司） 遊 控 股 有 限 公 司 Forgame Holdings Limite d Annu al Rep ort 2024 年度報告 | Contents | 目錄 | | | | --- | --- | --- | --- | | 2 | Corporate Information | 公司資料 | | | Financial Highlights | 5 | 財務摘要 | | | 7 | Chairman's Statement | 主席報告書 | | | 9 | Report of Directors | 董事會報告 | | | Management Discussion And Analysis | 43 | 管理層討論與分析 | | | 54 | Corporate Governance Report | 企業管治報告 | | | 85 | Biogr ...

「資本開支 下 表 列 示 於 所 示 期 間 我 們 的 資 本 開 支： 截至十二月三十一日止年度 二零二四年 二零二三年 人民幣千元 人民幣千元 購 買 物 業、廠 房 及 設 備 6,822 30,922 就 收 購 物 業、廠 房 及 設 備、無 形 資 產 以 及 專有技術支付的按金 48,153 13,569 購買無形資產 222 65 總 計 55,197 44,556 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：01345） 截至二零二四年十二月三十一日止年度之年度業績公告之澄清公告 茲提述上海先鋒控股有限公司（「本公司」）日期為二零二五年三月二十八日的截 至二零二四年十二月三十一日止年度之年度業績公告（「年度業績公告」）。除 非 文 義 另 有 所 指，否 則 本 公 告 所 用 詞 匯 與 年 ...

2024 2024 年度 報告 Annual Report ANNUAL REPORT 2024 年度報告 目錄 | 公司資料 | 2 | | --- | --- | | 主席報告書 | 3 | | 物業項目概要 | 5 | | 管理層討論及分析 | 8 | | 本公司董事及本集團高級管理人員之履歷 | 30 | | 董事會報告 | 33 | | 企業管治報告 | 41 | | 環境、社會及管治報告 | 53 | | 獨立核數師報告 | 88 | | 綜合損益表 | 95 | | 綜合損益及其他全面收益表 | 96 | | 綜合財務狀況表 | 97 | | 綜合權益變動表 | 99 | | 綜合現金流量表 | 102 | | 綜合財務報表附註 | 104 | | 五年財務概要 | 258 | | 於二零二四年十二月三十一日持有之主要物業 | 259 | 公司資料 董事會 執行董事 林曉輝 （主席） 蘇嬌華 （行政總裁） 林曉東 獨立非執行董事 余亮暉 方吉鑫 何振琮 審核委員會 余亮暉 （主席） 方吉鑫 何振琮 薪酬委員會 方吉鑫 （主席） 林曉輝 余亮暉 提名委員會 林曉輝 （主席） 余亮暉 方吉鑫 公司秘 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔 任 何 責 任。 00991 海外監管及內幕消息公告 2025 第一季度報告 根 據 中 國 證 券 監 督 管 理 委 員 會 的 規 定，大 唐 國 際 發 電 股 份 有 限 公 司（「本 公 司」或「公 司」）需 於 第 一 季 度 和 第 三 季 度 刊 發 季 度 報 告。本 季 度 報 告 內 所 載 的 財 務 數 據 均 未 經 審 計，並 根 據 中 國 企 業 會 計 準 則 而 編 製。本 公 告 乃 為 本 公 司 根 據 證 券 及 期 貨 條 例（ 香港法例第 571 章）第 XIVA 部下之內幕消息條文 （根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）下 所 定 義）及 上 市規則第 13.09(2)(a) 及 13.10B 條 的 規 定 所 發 出。 重 要 內 容 提 示： 公 司 ...

ANNUAL REPORT 年 報 2024 Annual Report 2024 年報 CORPORATE PROFILE 公司簡介 China Mengniu Dairy Company Limited (the "Company"; stock code: 2319) and its subsidiaries (collectively the "Group" or "Mengniu") mainly manufacture and distribute quality dairy products in China. It is one of the leading dairy product manufacturers in China, with MENGNIU as its core brand. Mengniu offers diversified products including liquid milk products, ice cream, milk formula and cheese. Mengniu ranked ninth in the 2024 "Global Dairy ...